CTRI/2020/04/024806招募中2 期
Efficacy of Imatinib in mild SARS CoV2 infection: A randomized study
试验速览
- 阶段
- 2 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a)Age -18 years and above (no upper age limit )
- •b)Mildly symptomatic Patients admitted in the AIIMS hospital with a proven diagnosis of COVID 19 infection on RT-PCR, with National Early Warning Score (NEWS score) <=3
排除标准
- •a)Abnormal Liver function at baseline, i.e. Serum Bilirubin > 1.5 ULN, ALT and AST > 3 ULN. Upto 5 times in case of chronic liver disease.
- •b)Abnormal renal functions at baseline, i.e.. Serum creatinine > 1.5 ULN
- •c)Prior history of exposure to imatinib
- •d)Any other condition assessed by physiciansâ?? team that will lead to difficulty in carrying out the trial.
- •e)Pregnant or breast feeding women.
- •f)Patients unable to swallow oral medicines.
研究者
相似试验
进行中（未招募）
1 期
intedanib for the treatment of pulmonary fibrosis induced by Covid-19Patients 2 to 6 months after Covid-19 acute pneumoniaEUCTR2020-002114-40-FRAssistance Publique - Hôpitaux de Paris250
Unknown
3 期
The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced PneumoniaCOVID-19NCT04422678Alexandria University30
进行中（未招募）
4 期
Study to compare the effect of different antiviral medicines in COVID-19 infected sick childreCTRI/2020/10/028234Dept of Pediatrics Medical College Kolkata
招募中
不适用
Treatment of Sars-CoV2 infections (Covid-19) with valsartan vs placebo, a three-armed randomized, partly blinded trialCovid-19DRKS00021732Klinikum St. Georg gGmbH300
尚未招募
不适用
se of Hemopurifier Device For The Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans.CTRI/2021/10/037591Aethlon Medical Inc